Three cases-one for the colon, a second in cardiology, and a third addressing the liver-will serve as the playing fields for this year’s Workstation Face-Off. Seven companies will go head to head Wednesday May 19 from 3:30 to 6 p.m. with luminaries putting their workstations through carefully choreographed steps.
Three cases-one for the colon, a second in cardiology, and a third addressing the liver-will serve as the playing fields for this year’s Workstation Face-Off. Seven companies will go head to head Wednesday May 19 from 3:30 to 6 p.m. with luminaries putting their workstations through carefully choreographed steps.
Vital Images will bring three physician-customers to champion their product; GE Healthcare will bring two . Philips, Siemens, Carestream, TeraRecon, and Ziosoft will each field just one operator. All operators will follow exactly the same instructions, demonstrating workflow and image quality on their respective workstations, all within the same four-minute time frame for each case.
Case 1 – Screening for colon polyps:
Case 2 – Aortic valvular stenosis as part of a preoperative evaluation:
Case 3 – Evaluation of a patient with metastatic cholangiocarcinoma on experimental treatment:
Rules of engagement prohibit the use of prerendering.
“No matter how fast you can switch from screen to screen to pick up on presaved views, the sophisticated audience can see what you are doing,” the rules advise.
If Face-Off moderator Dr. Geoffrey Rubin does as he has in the past, he will remind operators to fully magnify and zoom in on findings, a rule often overlooked under the time constraints of the demonstrations, time constraints that have been, and will be again this year, strictly enforced.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.